Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
The data showed that 1,273 (4·8%) of 26,438 eligible individuals were positive for Ebola virus disease (cases), and 25,165 (95·2%) were negative (controls).Merck & Co Inc's (NYSE:MRK) rVSV-ZEBOV vaccine is the only WHO-prequalified vaccine endorsed by the Strategic Advisory Group of Experts on Immunization for use in Ebola outbreaks caused by the Zaire ebolavirus.
默沙东公司的rVSV-ZEBOV疫苗是世界卫生组织预认证的唯一一种生物-疫苗，也是由免疫战略咨询专家组认可用于由扎伊尔伊博拉病毒引起的埃博拉疫情的疫苗。
The FDA approved the vaccine for adults in December 2019 and for use in children 12 months and older in August 2023.
FDA于2019年12月批准该疫苗供成年人使用，并于2023年8月批准供12个月及以上的儿童使用。
Researchers conducted a retrospective test-negative analysis to estimate the effectiveness of rVSV-ZEBOV vaccination against Ebola virus disease during the 2018–20 epidemic in the Democratic Republic of the Congo.
研究人员进行了一项回顾性负阴性分析，估计了rVSV-ZEBOV疫苗在刚果民主共和国2018-20年疫情期间对埃博拉病毒疾病的有效性。
The data showed that 1,273 (4·8%) of 26,438 eligible individuals were positive for Ebola virus disease (cases), and 25,165 (95·2%) were negative (controls).
数据显示，在26,438名符合条件的个体中，有1,273人（4.8％）被检测出感染埃博拉病毒（病例），25,165人（95.2％）为阴性（对照组）。
Also Read: Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst.
同时阅读：默沙东以13亿美元收购潜在的免疫性疾病候选者对Cullinan的调查药物具有相关意义，分析师表示。
40 (3·1%) cases and 1271 (5·1%) controls were reported as being vaccinated at least ten days before symptom onset.
有40例（3.1％）病例和1271例（5.1％）对照报道称症状出现前至少十天接种了疫苗。
After selecting individuals who reported exposure to an individual with Ebola virus disease within 21 days before symptom onset and matching, the analysis datasets comprised a median of 309 cases and 309 controls.
在选择报告在症状出现前21天内接触到埃博拉病毒感染者的个体并进行匹配后，分析数据集包括了一个中位数为309例病例和309例对照。
Ten days or more after vaccination, the effectiveness of rVSV-ZEBOV against Ebola virus disease was estimated to be 84%.
疫苗接种后十天或更长时间，rVSV-ZEBOV对埃博拉病毒疾病的有效性估计为84％。
The researchers add that the analysis provides the first real-world effectiveness estimates for the rVSV-ZEBOV Ebola vaccine during a large outbreak.
研究人员补充说，这项分析提供了rVSV-ZEBOV埃博拉疫苗在大规模爆发期间的首个实际有效性估计。
The findings confirm the vaccine is highly effective against Ebola virus disease and support its use in outbreaks, even in challenging environments like the Eastern Democratic Republic of the Congo.
研究结果证实了该疫苗对埃博拉病毒疾病的高度有效性，并支持其在爆发期间的使用，即使在像刚果民主共和国东部这样具有挑战性的环境中也是如此。
The real-world effectiveness of rVSV-ZEBOV vaccination is expected to be less than 100%.
rVSV-ZEBOV疫苗的实际有效性预计低于100%。
During the 2018–20 outbreak in the Democratic Republic of the Congo, national and international agencies recorded confirmed cases of Ebola virus disease in vaccinated individuals, including individuals who were reported as having been vaccinated ten days or more before symptom onset.
在刚果民主共和国2018年至2020年的疫情期间，国家和国际机构记录了接种rVSV-ZEBOV疫苗的人员中的埃博拉病毒疾病确诊病例，包括在出现症状起十天或更长时间之前接种疫苗的人员。
Preliminary, unadjusted analyses estimated vaccine effectiveness to be 98%. Other studies have shown that rVSV-ZEBOV vaccination reduces the risk of death in patients with Ebola virus disease who were vaccinated before and even after exposure.
初步、未经调整的分析估计该疫苗的有效性为98%。其他研究表明，rVSV-ZEBOV疫苗降低了已接种疫苗的埃博拉病毒疾病患者死亡风险，甚至在暴露之前和之后的接种都有效。
Price Action: MRK stock is up 0.16% to $116.22 at the last check on Thursday.
股票价格：默沙东股票最近一次检查时上涨0.16%，至116.22美元。
- TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside.
- transmedics公司的科技有望改变80亿美元的器官移植市场，并增加22%的上涨空间，分析师预计。
